217 related articles for article (PubMed ID: 25498455)
1. Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Famà R; Bomben R; Rasi S; Dal Bo M; Ciardullo C; Monti S; Rossi F; D'Agaro T; Zucchetto A; Gattei V; Gaidano G; Rossi D
Blood; 2014 Dec; 124(25):3831-3. PubMed ID: 25498455
[No Abstract] [Full Text] [Related]
2. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Jones D; Woyach JA; Zhao W; Caruthers S; Tu H; Coleman J; Byrd JC; Johnson AJ; Lozanski G
Leukemia; 2017 Jul; 31(7):1645-1647. PubMed ID: 28366935
[No Abstract] [Full Text] [Related]
3. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
[TBL] [Abstract][Full Text] [Related]
4. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Lenz G
J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
[No Abstract] [Full Text] [Related]
5. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib resistance in chronic lymphocytic leukemia.
Furman RR; Cheng S; Lu P; Setty M; Perez AR; Guo A; Racchumi J; Xu G; Wu H; Ma J; Steggerda SM; Coleman M; Leslie C; Wang YL
N Engl J Med; 2014 Jun; 370(24):2352-4. PubMed ID: 24869597
[No Abstract] [Full Text] [Related]
7. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
8. Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Albitar A; Ma W; DeDios I; Estella J; Ahn I; Farooqui M; Wiestner A; Albitar M
Oncotarget; 2017 Mar; 8(11):17936-17944. PubMed ID: 28212557
[TBL] [Abstract][Full Text] [Related]
9. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
[TBL] [Abstract][Full Text] [Related]
10. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
11. BTK
Woyach JA; Ruppert AS; Guinn D; Lehman A; Blachly JS; Lozanski A; Heerema NA; Zhao W; Coleman J; Jones D; Abruzzo L; Gordon A; Mantel R; Smith LL; McWhorter S; Davis M; Doong TJ; Ny F; Lucas M; Chase W; Jones JA; Flynn JM; Maddocks K; Rogers K; Jaglowski S; Andritsos LA; Awan FT; Blum KA; Grever MR; Lozanski G; Johnson AJ; Byrd JC
J Clin Oncol; 2017 May; 35(13):1437-1443. PubMed ID: 28418267
[TBL] [Abstract][Full Text] [Related]
12. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
13. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Wu J; Zhang M; Liu D
Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies: ibrutinib resonates with us.
Villanueva MT
Nat Rev Clin Oncol; 2014 Jul; 11(7):380. PubMed ID: 24935013
[No Abstract] [Full Text] [Related]
15. Second-generation inhibitors of Bruton tyrosine kinase.
Wu J; Liu C; Tsui ST; Liu D
J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
[TBL] [Abstract][Full Text] [Related]
16. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
[No Abstract] [Full Text] [Related]
17. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Burger JA; Landau DA; Taylor-Weiner A; Bozic I; Zhang H; Sarosiek K; Wang L; Stewart C; Fan J; Hoellenriegel J; Sivina M; Dubuc AM; Fraser C; Han Y; Li S; Livak KJ; Zou L; Wan Y; Konoplev S; Sougnez C; Brown JR; Abruzzo LV; Carter SL; Keating MJ; Davids MS; Wierda WG; Cibulskis K; Zenz T; Werner L; Dal Cin P; Kharchencko P; Neuberg D; Kantarjian H; Lander E; Gabriel S; O'Brien S; Letai A; Weitz DA; Nowak MA; Getz G; Wu CJ
Nat Commun; 2016 May; 7():11589. PubMed ID: 27199251
[TBL] [Abstract][Full Text] [Related]
18. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Lampson BL; Brown JR
Expert Rev Hematol; 2018 Mar; 11(3):185-194. PubMed ID: 29381098
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Mazzucchelli M; Cairoli R; Montillo M
Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib-Induced Lymphocytosis: Cytological Features.
Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
[No Abstract] [Full Text] [Related]
[Next] [New Search]